메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
권준하 (한국과학기술원) 이준형 (한국과학기술원) 이영한 (연세대학교) 이지연 (성균관대학교) 안진희 (울산대학교) 김세현 (분당서울대학교병원) 김승현 (연세대학교) 김태일 (연세대학교) 윤금희 (연세대학교) 박영석 (성균관대학교) 김정은 (울산대학교) 이규상 (분당서울대학교병원) 최정균 (한국과학기술원) 김효송 (연세대학교)
저널정보
대한암학회 Cancer Research and Treatment Cancer Research and Treatment 제54권 제4호
발행연도
2022.10
수록면
1,240 - 1,255 (16page)
DOI
10.4143/crt.2021.1194

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Purpose Desmoid tumor, also known as aggressive fibromatosis, is well-characterized by abnormal Wnt/β-catenin signaling. Various therapeutic options, including imatinib, are available to treat desmoid tumor. However, the molecular mechanism of why imatinib works remains unclear. Here, we describe potential roles of <i>NOTCH2</i> and <i>HES1</i> in clinical response to imatinib at genome and transcriptome levels.Materials and Methods We identified somatic mutations in coding and noncoding regions via whole-genome sequencing. To validate the genetic interaction with expression level in desmoid-tumor condition, we utilized large-scale whole-genome sequencing and transcriptome datasets from the Pan-Cancer Analysis of Whole Genomes project. RNA-sequencing was performed using prospective and retrospective cohort samples to evaluate the expressional relevance with clinical response.Results Among 20 patients, four (20%) had a partial response and 14 (66.7%) had stable disease, 11 of which continued for ≥ 1 year. With gene-wise functional analyses, we detected a significant correlation between recurrent <i>NOTCH2</i> noncoding mutations and clinical response to imatinib. Based on Pan-Cancer Analysis of Whole Genomes data analyses, <i>NOTCH2</i> mutations affect expression levels particularly in the presence of CTNNB1 missense mutations. By analyzing RNA-sequencing with additional desmoid tumor samples, we found that <i>NOTCH2</i> expression was significantly correlated with <i>HES1</i> expression. Interestingly, <i>NOTCH2</i> had no statistical power to discriminate between responders and non-responders. Instead, <i>HES1</i> was differentially expressed with statistical significance between responders and non-responders.Conclusion Imatinib was effective and well tolerated for advanced desmoid tumor treatment. Our results show that <i>HES1</i>, regulated by <i>NOTCH2</i>, as an indicator of sensitivity to imatinib, and an important therapeutic consideration for desmoid tumor.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0